B4GALT3
- Known as:
- B4GALT3
- Catalog number:
- 002370A
- Product Quantity:
- 250ul
- Category:
- -
- Supplier:
- ABM
- Gene target:
- B4GALT3
Related genes to: B4GALT3
- Gene:
- B4GALT3 NIH gene
- Name:
- beta-1,4-galactosyltransferase 3
- Previous symbol:
- -
- Synonyms:
- beta4Gal-T3
- Chromosome:
- 1q23.3
- Locus Type:
- gene with protein product
- Date approved:
- 1998-12-02
- Date modifiied:
- 2016-03-15
Related products to: B4GALT3
Related articles to: B4GALT3
- The genesis of Parkinson's disease (PD), a common central neurodegenerative disorder, involves dysregulation of protein posttranslational modifications (PTM). The primary objective of this study was to screen key PTM-associated genes (PTMGs) serving as diagnostic indicators and potential therapeutic targets in PD. - Source: PubMed
Publication date: 2026/07/24
Wang BangzhiHuang ZhuoWang RongZhu ChaolinMa ShijiangWang Minghong - (1) Background: Although the rhesus macaque () is widely maintained in captive populations for translational research, reliable molecular tools for monitoring their physiological status remain limited-a gap that directly affects population management and health monitoring. In particular, no validated panel of housekeeping genes (HKGs) is currently available for expression analysis at the mRNA level in peripheral blood of the species. (2) Methods: Peripheral blood samples from healthy male rhesus macaques aged 4-7 years were used. The expression stability of candidate HKGs was evaluated using RefFinder based on cycle threshold (Ct) values obtained from real-time PCR. (3) Results: A panel of 29 candidate HKGs was compiled. After multistage bioinformatic and experimental selection, 22 genes were excluded. Expression stability analysis of the remaining seven genes (, , , , , , and ) identified and as the most stable. (4) Conclusions: This study presents the experimentally validated set of HKGs for expression studies in . Based on the results of expression stability analysis, the and genes can be recommended as reference genes for studying changes in gene expression in peripheral blood. - Source: PubMed
Publication date: 2026/06/24
Kumakov Ivan RShulskaya Marina VShamsutdinova Olga ABulgin Dmitry VShadrina Maria ITrashkov Alexandr PSlominsky Petr AAlieva Anelya Kh - Aberrant protein glycosylation contributes significantly to hepatocellular carcinoma (HCC) progression. β-1,4-Galactosyltransferase 3 (B4GALT3), an enzyme involved in glycosylation, is overexpressed in HCC and promotes tumour growth by stabilizing integrin β1 (ITGB1). This study aimed to evaluate B4GALT3 as a therapeutic target and develop a precision nanotherapeutic approach for HCC. - Source: PubMed
Publication date: 2026/05/19
Yu XiaohuiChen XiaoyanGuo HuiJin XiaTan PingpingZeng LongwuHe YanLi Junjun - Genome-wide studies in late-onset Alzheimer's disease (LOAD) have uncovered many risk loci, yet identifying the causal genes and clarifying how these genetic signals connect to molecular and cellular mechanisms relevant to AD pathogenesis remains challenging. - Source: PubMed
Publication date: 2026/03/30
Waghmare Swapnil GKrishna Meera MMaccoux Emily CFranitza Ariel LLink Brian ALezi E - Bladder cancer (BLCA) poses a significant clinical challenge due to its high mortality rates and the inadequacy of current prognostic biomarkers. Programmed cell death (PCD) is crucial in BLCA initiation, progression, and treatment, yet the interplay and specific roles of different PCD pathways in BLCA prognosis remain elusive. This study aimed to develop and validate predictive models by integrating 14 PCD patterns using comprehensive analyses of bulk RNA and single-cell RNA transcriptomic data from TCGA-BLCA and six GEO datasets. Through weighted gene co-expression network (WGCNA) analyses, 24 hub PCD-related genes (PCDGs) were identified in BLCA. Subsequently, we implemented a computational framework that integrated 10 machine learning algorithms along with 101 of their combined permutations. This framework was used to develop a programmed cell death-related signature (PCDRS). The final PCDRS consisted of 12 prognostic genes: P4HB, CHEK2, PTPN2, ATP13A2, CCT6A, TFRC, RRP12, TRAF7, POLR1B, B4GALT3, SIVA1, and TP73.The PCDRS was validated in training and external validation sets, with multivariate analysis confirming its independent prognostic value in BLCA. The PCDRS-integrated nomogram was also developed as a quantitative clinical tool. Furthermore, differences in reactive oxygen species (ROS) levels were observed in the tumor microenvironment between high- and low-risk groups based on PCDRS risk scores. Additionally, the elevated expression and tumorigenic role of P4HB in BLCA were validated through in vitro assays. In summary, P4HB may serve as a candidate gene with potential relevance to BLCA prognosis that could enhance personalized treatment strategies for patients with BLCA. - Source: PubMed
Publication date: 2026/04/02
Cao YangLi CanHua YiboWu TingtingShen QiuyuLin ZeyuHuang Yuhua